Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Systems biology approaches to understand cell pluripotency Acronym: PluriSys (PLURISYS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Hungary,Netherlands,Germany,France,Denmark,United Kingdom,Italy
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3842833.6
EU funding (EUR): 2965438.0
Participants: 7
Project status: CLOSED

The PluriSys project is aimed at increasing the fundamental knowledge of basic biological processes of cell pluripotency and differentiation by generating new holistic data on gene expression and epigenetic modifications associated with cell pluripotency. The project integrates the multidisciplinary excellence in Europe in cell biology, molecular biology and bioinformatics. It also builds on earlier efforts, as consortium partners are leading partners in several EU funded projects in these areas. The PluriSys project links for the first time research activities in different mammalian systems, including murine, porcine and bovine, and in different cell types, from pluripotent cells in pre-implantation embryos, through embryonic stem cells, to epiblast-derived stem cells. Novel bioinformatics approaches and tools will be developed to set common standards for data analyses among all consortium members and, at a wider scale, to provide an integrated data base matching the requirements of systems biologists. Training, education and outreach activities are structured to assure the maximum efficiency in developing and spreading the new standards and to increase the impact of the project for the European Health sector. The project integrates SME partners and academic institutions from 7 countries from all regions of the EU and will help to decrease the fragmentation of ERA. The main impact of the project is expected as integrating efforts in cell biology, cell therapy, molecular biology and bioinformatics for future applications of systems biology on the relevant questions of cell pluripotency and differentiation. Furthermore, the project is expected to yield pracically useful results, such as improved procedures for the derivation, maintenance and differentiation of pluripotent stem cell lines in mouse and large animals, with potential future applications in the fields of regenerative medicine and tissue engineering, and, beyond these areas, in pharmaceutical industry and

Keywords: pluripotency,stem cells,embryos,bioinformatics,system biology,epiblast,embryonic stem cells,human,mouse,bovine,pig
Temptations to Eat Moderated by Personal and Environmental Self-regulation Tools (TEMPEST)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Belgium,Denmark,Germany,Poland,Portugal,Romania,United Kingdom,Finland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2013-01-31
Duration (months): 48.0
Total project cost (EUR): 3205495.0
EU funding (EUR): 2404118.0
Participants: 9
Project status: CLOSED

The prevalence of overweight amongst European children and adolescents has risen at an alarming rate in the past decades, with major repercussions for their health in the short and long term. Existing prevention programmes to combat the epidemic either highlight a public health approach (employing incentive schemes such as taxing of foods) or an individual-educational approach to encourage young people to adopt a healthy lifestyle. Until now, both approaches have met with limited success. The aim of the TEMPEST project is to investigate how both approaches may complement each other in order to develop more effective preventive interventions. Public health approaches to prevent overweight are important as they are easy-to-implement and can be employed independently from active participation of the target group. However, they may be powerless in an ‘obesogenic’ environment that is characterized by huge amounts of food and inactivity temptations. The TEMPEST project introduces the novel concept of self-regulatory competence (SRC; the ability to inhibit unwanted responses to temptations) for dealing with such temptations as the key factor in prevention of overweight. The main hypothesis states that increasing SRC allows youth to take better advantage of public health efforts that draw on (non)financial incentive schemes, and will be examined in nine European countries which vary in their public health policies and programmes. The project has four major objectives: 1) Develop a youth-specific SRC Scale for dealing with weight-related temptations that is culturally valid across Europe; 2) Determine the impact of existing incentive schemes and other socio-economic and socio-cultural factors on SRC and weight-related behaviours; 3) Examine the influence of new, experimental incentive schemes on SRC and weight-related behaviours; and 4) Determine the impact of temptations on SRC and weight-related behaviours in social contexts that differ in their appreciation of SRC.

Keywords: adolescents,children,eating behaviour,self-regulation,incentive schemes,overweight
Safety Of non-Steroidal anti-inflammatory drugs (SOS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Netherlands,Spain,United Kingdom,Italy,United States,Germany,Canada,France,Netherlands,Italy
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-04-30
Duration (months): 42.0
Total project cost (EUR): 3767705.01
EU funding (EUR): 2800000.0
Participants: 11
Project status: CLOSED

The Safety Of non-Steroidal anti-inflammatory drugs (SOS) proposal aims to assess the relative cardiovascular (CVD) and gastrointestinal (GI) safety of non-steroidal anti-inflammatory drugs (NSAIDs). The NSAIDs are divided in traditional NSAIDs (tNSAIDs) and the newer COX-II inhibitors(coxibs). The aim will be fulfilled by a two-phase approach comprising systematic reviews and synthesis of CVD and GI risk information from clinical trials and published observational studies, followed by the design and conduct of a multi-country study in existing health care databases in the UK, Netherlands, Germany and France, comprising medical information on at least 35 million persons. A data ware house will be constructed that will contain all pre-specified and locally elaborated anonimized data from inception cohorts of NSAID users. Data elaboration is standardized through a common protocol that will be designed on the basis of information and knowledge gaps observed in the systematic literature reviews, plus information requirements for the statistical and decision models. The database study will yield risk estimates for CVD and GI bleeding for each individual NSAID by dose and duration and by other important effect modifiers (e.g. aspirin use). Separate models will be built for children since the indications and dosages differ and little is known on the safety of NSAIDs in this group as they are often prescribed off-label. Special emphasis will be put on the assessment and evaluation of methodological issues, such as confounding by indication, and outcome validity as these constitute the most important threats to the interpretation, robustness and perceived validity of observational studies. The results of the literature reviews, analysis of observational databases and re-analysis of published studies will feed into a decision model for clinicians to support treatment decisions and a decision model for regulatory authorities that will focus on the public health risk.

Keywords: nsaids,risk,cardiovascular,gastrointestinal,decision model,databases,observational
European Management Platform for Emerging and Re-emerging Infectious disease Entities (EMPERIE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Germany,France,Hong Kong,Netherlands,United Kingdom,United Kingdom,United Kingdom,Spain,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-05-01
End date: 2014-04-30
Duration (months): 60.0
Total project cost (EUR): 15967125.2
EU funding (EUR): 11909560.0
Participants: 12
Project status: CLOSED

The EMPERIE (European Management Platform for Emerging and Re-emerging Infectious disease Entities) consortium has its roots in the lessons learned by the majority of the participating centres during the recent SARS and HPAI H5N1 outbreaks. The mission of EMPERIE is “to contribute to effectively countering the potential public health threat caused by new and emerging infectious diseases in Europe by establishing a powerful network capable of structural and systematic prediction, identification, modelling and surveillance of infectious diseases health threats and pathogens”. In pursuit of this mission EMPERIE will establish a network of centres of excellence combining the expertise, techniques and resources necessary for effectively countering (re)-emerging infectious diseases. We will establish common processes, procedures and communication channels in the network linked to relevant stakeholder organisations and local “grass root”” sites to contribute to a structural and systematic prediction, identification, modelling and surveillance of (re-)emerging infectious disease health threats and pathogens. Our focus will be new zoonotic viruses that may cause epidemics and viruses already present – but yet unrecognised- in humans. Within this focus, we will attain proof of principle of the functioning of the network and the techniques, systems, procedures and resources in the following RNA viruses: Flaviviruses (e.g. Dengue, West-Nile virus), Alphaviruses (e.g. Chikungunya), Orthomyxoviruses (e.g. Influenza), Paramyxoviruses (e.g Henipah,) Coronaviruses, Bunyaviruses ( e.g. hantavirus) and Filoviruses

Keywords: network on prediction,identification,modelling and surveillance of infectious diseases health threats and pathogens
Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges. (INYVAX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: France,Switzerland,Netherlands,Switzerland,Denmark,Netherlands,Germany,United States
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2012-01-31
Duration (months): 36.0
Total project cost (EUR): 1168634.53
EU funding (EUR): 932335.0
Participants: 10
Project status: CLOSED

A number of new vaccines are being developed against Poverty-Related infectious diseases of major public health importance at a global level. The development of all those vaccines is facing the same kind of challenges and gaps, which still prevent 1) the establishment of readily accessible formulation and scale-up process development capacity for neglected diseases vaccines. 2) the establishment of a systematic approach for prioritizing formulation of vaccine candidates using accepted pre-clinical criteria. 3) the development of information-sharing tools to strengthen connections between the scientists, the developers and the clinical investigators. To address those challenges, the European vaccine community needs to establish a shared vision and goals and to identify the activities that could address some of the above-mentioned challenges. The cooperation between the different groups of PRD vaccine developers can bring innovative approaches for accelerating the development of effective vaccines. Among those challenges, several can be addressed through coordination across poverty related diseases, such as: 1) difficulties in accessing to some technology platforms, such as synthetic peptides, recombinant proteins, … for GMP development, and therefore in making rationale decisions on the best industrial approach for the pharmaceutical development, 2) difficulties in accessing certain know-how, such as lyophilisation and lack of formulation platform accessible to academic group, 3) difficulties to access to some delivery platforms, such as adjuvants, virus-like particles … for GMP development and/or to assess the quality and regulatory compliance of those platforms, 4) difficulties to harmonise the safety data collection, 5) the insufficient number of trained scientists able to play leadership in vaccine development

Keywords: malaria vaccine
Building a Tool to Evaluate and Improve Health Investments in Screening and Diagnosis of disease (HISCREENDIAG)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Belgium,Spain,Germany,Netherlands,United Kingdom,European organisations area
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2011-02-28
Duration (months): 24.0
Total project cost (EUR): 473327.4
EU funding (EUR): 438885.0
Participants: 6
Project status: CLOSED

Over recent decades, the possibilities for the prevention, diagnosis and treatment of disease have expanded throughout the EU. As a result, health policy decision makers and public funders are faced with the challenge of making choices for health investments to improve the healthy life expectancy of Europeans within the context of constrained resources. Health investments include any new technology for the diagnosis, prevention or treatment of disease. It is not clear to which extent recent decisions on such health investments have been optimal. Public funders sometimes evaluate the impact of health investments, but there is a lack of standardised procedures and criteria. This is even more the case for investments related to screening and diagnosis of disease, and in particular gene technologies. The objectives of this study are: 1. to set up a set of common criteria (a ‘tool’) for the evaluation of health investments related to screening and diagnosis (HISD) in Europe, with a special focus on gene technologies; 2. to guide the better alignment of procedures between all (old and new) MS; and 3. to improve the effectiveness and cost-effectiveness of future HISD. Literature reviews will identify existing methods for evaluating health investments and summarise existing procedures and criteria within member states (MS) for making and evaluating decisions on HISD. In parallel, stakeholders will be invited to participate in a survey allowing a better understanding of the commonalities and differences between MS. Based on this, a draft tool, comprising procedures and criteria for evaluating HISD will be proposed. The draft tool will be assessed by a panel of experts guiding its iterative development. A list of recent HISD in MS will then serve as subject for testing the practical applicability of the tool. Finally, ways for implementing the tool and for the evaluation of HISD in MS will be proposed together with recommendations and political implications at EU level.

Keywords: health investments,cost-effectiveness,decision making process,evaluation tool,screening,diagnosis
GridTalk: co-ordinating grid reporting across Europe (GRIDTALK)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to policy development and Programme implementation
Action type: Coordination and support actions
Countries involved: United Kingdom,France,Switzerland
Call:  (FP7-INFRASTRUCTURES-2007-2, 2007)
Start date: 2008-05-01
End date: 2010-08-31
Duration (months): 28.0
Total project cost (EUR): 607249.0
EU funding (EUR): 500000.0
Participants: 3
Project status: CLOSED

The impact of Grids has rapidly expanded beyond that which can be disseminated by individual projects. GridTalk will bring the success stories of Europe's e-Infrastructure to policy makers in government and business, to the broader scientific community, and to the general public. The project will co-ordinate the dissemination outputs of EGEE and other European Grid efforts, ensuring their results and influence are reported widely in print and online. GridTalk’s output will come in three main forms. Firstly, a series of reports and briefings will engage policy makers with the specific achievements and impacts of Europe’s science Grids. Secondly, the high profile GridCafé website will be extended to ensure its continued success in informing the general public. And finally international Science Grid This Week, the rapidly growing online newsletter, will provide a resource for scientists using Grid computing and for those considering becoming involved. Through its international, cross-disciplinary approach, GridTalk will play a vital role in encouraging participation in and co-ordination between Grid projects in Europe, and in particular in preparing for the proposed European Grid Infrastructure and other initiatives aimed at a sustainable e-Infrastructure in Europe. It will also spread awareness of Europe’s leading role in Grid development to other geographical areas.

Keywords: grid,e-infrastructure. science,dissemination,policy,impact
A systems approach linking genotype and environment to phenotype: oxidative stress response mechanisms in fission yeast (PHENOXIGEN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Denmark,Switzerland,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-03-31
Duration (months): 42.0
Total project cost (EUR): 3242580.0
EU funding (EUR): 2475460.0
Participants: 4
Project status: CLOSED

Cellular protection against oxidative damage is relevant to ageing and numerous complex diseases. We plan to use fission yeast as a model organism to gain a systems-level understanding of the oxidative stress response and obtain insights into the interplay of variable genotype, phenotype, and environment. To this end, the four participants will pursue a range of multi-disciplinary and complementing approaches that will be integrated with innovative computational methods for a unified view of a complete regulatory system. We will create a genetically and phenotypically diverse library of yeast strains from crosses of three independent parental strains with distinct stress sensitivities. The parental and segregant strains will be genotyped and phenotyped (in stressed and unstressed cells) using state-of-the-art sequencing, tiling array, and proteomics approaches, thus providing a rich basis for genome-wide association studies and computational modelling. Genetic, functional genomic, and proteomic approaches, along with computational methods, will be applied in parallel to develop protein and gene interaction networks that will further support the modelling efforts. Predictions based on the modelling will be validated with targeted wet-lab experiments to test and refine the mathematical models. Intimate inter-dependency between experimental and bioinformatic approaches based on close collaboration among participants with different expertise will be vital to develop successful models predicting the regulatory response to oxidative stress. The relative simplicity of yeast cells, which can be grown under tightly controlled conditions and with defined genetic and environmental perturbations, promises a thorough and deep understanding of the oxidative stress response system. Concepts developed in the proposed study will provide a valuable framework for research into more complex systems such as response networks and association studies in human cells.

Keywords: oxidative stress,pathway modelling,quantitative trait loci,posttranscriptional regulation
The Physiological Basis of Hypervirulence in Clostridium difficile: a Prerequisite for Effective Infection Control (HYPERDIFF)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Italy,France,Netherlands,United Kingdom,Slovenia,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2011-10-31
Duration (months): 36.0
Total project cost (EUR): 3940839.0
EU funding (EUR): 2992181.0
Participants: 7
Project status: CLOSED

Clostridium diffficile is currently wreaking havoc within European health systems due to the emergence of hyper virulent strains, responsible for more severe disease, higher relapse rates, increased mortality and greater resistance to antibiotics. Its impact in healthcare settings is considerable, in terms of morbidity, mortality and financial cost However, the physiological basis of pathogenesis is poorly understood due to an absence of mutational tools for functional genomic studies. This bottleneck has been solved by partner 1 who has developed the ‘ClosTron’, a highly efficient gene knock-out tool. This will be used to systematically inactivate those chromosomal genes which encode products hypothesised to be involved in pathogenesis, and an assessment of the consequences made in models of infection. To ascertain the prevalence of the identified hyper virulence traits in the human and animal population, epidemiological studies will be undertaken. Special attention will be paid to the wider human population to gauge the prevalence of community acquired C. difficile. The identity of the determinants responsible for hyper virulence would allow the derivation of diagnostic tests directed specifically at those factors directly responsible for their spread within the healthcare setting. They will also allow the formulation of therapeutic countermeasures that could be deployed to both prevent and treat disease outbreaks. The objectives of HYPERDIFF will be met by a consortium of the leading EU researchers on C. difficile. It brings together a multidisciplinary team from a range of sectors and 6 member states. They are composed of 4 Universities, 2 Government Institutes, and a commercial company, with the key skills needed to deliver the objectives of HYPERDIFF. In combination with the unique ClosTron system, these capabilities will propel Europe to the forefront of the field.

Keywords: clostridium difficile,hypervirulence,epidemiology,physiology,nosocomial infection,prevention